New subscription platform brings validated nonprofit data into one workspace to save time; expands discovery beyond ...
Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...
Lehigh Valley Health Network has chosen Sodexo as its food provider at all LVHN locations, replacing Compass One Healthcare. The shift to Sodexo will be complete in March, according to an LVHN ...
The Jeep Compass still holds its spot as the entry point to the automaker’s SUV range, with compact size, standard all-wheel ...
Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...
Racing Post+ tipping is our top-tier betting advice service, starring our biggest and best experts. Sign up now to receive 35% off for a whole year, plus you’ll also have access to an enormous range ...
Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the ...
Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...
New research benchmarks 12 solution providers and reveals why AI interviewers are spreading faster than governance can ...
A Warning From Inside the Washington Post’s Unraveling MIAMI, FL, UNITED STATES, February 5, 2026 /EINPresswire.com/ -- ...
Upstart Holdings Inc. (NASDAQ:UPST) is one of the best growth stocks to buy for the next 20 years. On February 17, following ...
Clinical Trials Arena on MSN
Compass stock heads north on psychedelic’s Phase III TRD success
Compass will now seek approval for COMP360, which could become the first classic psychedelic to gain the FDA’s blessing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results